Preexposure prophylaxis (PrEP), coformulated as tenofovir (TFV), disoproxil fumarate (TDF), and emtricitabine (FTC), is a biomedical intervention that has demonstrated a reduction of human immunodeficiency virus (HIV) transmission rates by as much as 75% in heterosexual serodiscordant partnerships and up to 99% among men having sex with men (MSM) and transgender women when taken daily.^1,2 It was approved by the US Food and Drug Administration in 2012 for adults 18 years and older, but approval for adolescents younger than 18 years has stalled because of limited data on the efficacy, acceptability, and safety among adolescents younger than 18 years.

暴露前预防（PrEP），与替诺福韦（TFV），富马酸二甲吡咯酯（TDF）和恩曲他滨（FTC）共同配制，是一种生物医学干预措施，已证明可将人类免疫缺陷病毒（HIV）传播率降低75％每天服用男男性接触者（MSM）和变性女性的异性性伴侣关系高达99％。^{1 ，2}，于2012年获得美国食品和药物管理局成人18岁以上，但批准的青少年未满18岁的有青少年不满18岁之间的停顿，因为对疗效，接受有限的数据和安全性。